

- **Name:** David Braun
 - **Current Position & Affiliation:** Assistant Professor and the Louis Goodman and Alfred Gilman Yale Scholar, Yale Cancer Center, Yale School of Medicine
 - **Country:** USA
-

• **Educational Background:**

- 08/2002-05/2006 AB, Molecular Biology, Princeton University, Princeton, NJ
- 07/2008-09/2012 PhD, Computational Biology, Courant Institute, New York University, New York, NY
- 07/2006-06/2013 MD, Icahn School of Medicine of Mount Sinai, New York, NY

• **Professional Experience:**

- 06/2013-06/2014 Intern, Internal Medicine, Brigham and Women's Hospital / Harvard Medical School, Boston, MA
- 07/2014-06/2015 Resident, Internal Medicine, Brigham and Women's Hospital / Harvard Medical School, Boston, MA
- 07/2015-06/2016 Fellow in Medical Oncology, Dana-Farber Cancer Institute / Massachusetts General Hospital / Brigham and Women's Hospital / Harvard Medical School, Boston, MA
- 07/2016-06/2017 Chief Medical Resident, Internal Medicine, Brigham and Women's Hospital / Harvard Medical School, Boston, MA
- 07/2017-09/2019 Postdoctoral Fellow in Medical Oncology, Dana-Farber Cancer Institute / Harvard Medical School, Boston, MA
- 09/2019-12/2021 Instructor in Medicine and Physician in Genitourinary Oncology, Dana-Farber Cancer Institute / Harvard Medical School, Boston, MA
- 01/2022-present Assistant Professor, Department of Medicine (Medical Oncology), Yale School of Medicine
- 01/2022-present Full Member, Cancer Immunology Research Program, Yale Cancer Center
- 02/2022-present Affiliate Member, New York Genome Institute, New York, NY
- 02/2022-present Assistant Professor (secondary appointment), Department of Urology, Yale School of Medicine
- 05/2022-present Assistant Professor (secondary appointment), Department of Pathology, Yale School of Medicine

• **Professional Organizations:**

American Society for Clinical Investigation (ASCI)

American Society of Clinical Oncologists (ASCO)
European Society for Medical Oncologists (ESMO)
American Association for Cancer Research (AACR)
Society for Immunotherapy of Cancer (SITC)

• **Main Scientific Publications:**

1. **Braun DA**, et al. Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma. JAMA Oncol. 2019 Sep 05. PMID: 31486842; PMCID: PMC6735411.
2. **Braun DA**, et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020 Jun; 26(6):909-918. PMID: 32472114.
3. **Braun DA***, Street K*, et al. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell. 2021 Mar 09. PMID: 33711273.
4. Saliby RM... McKay RR*, **Braun DA***. Circulating and intratumoral immune determinants of response to atezolizumab plus bevacizumab in patients with variant histology or sarcomatoid renal cell carcinoma. Cancer Immunol Res. 2023 Jun 6:CIR-22-0996. doi: 10.1158/2326-6066.CIR-22-0996. Epub ahead of print. PMID: 37279009.
*Co-Senior, Co-Corresponding.
5. Saliby RM... **Braun DA**. Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes. Cancer Cell. 2024 Apr 4:S1535-6108(24)00087-4. doi: 10.1016/j.ccell.2024.03.002. Epub ahead of print. PMID: 38579722.
6. Jammihal T, Saliby RM...Choueiri TK*, **Braun DA***, Shukla SA*. Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma. Nat Cancer. 2025 Jan 9. doi: 10.1038/s43018-024-00896-w. Epub ahead of print. PMID: 39789182.
*Co-senior, co-corresponding authors
7. Xu W... Romee R*, Choueiri TK*, **Braun DA***. Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes. ESMO Open. 2025 Jan 14;10(2):104105. doi: 10.1016/j.esmoop.2024.104105. Epub ahead of print. PMID: 39813824.
*Co-senior, co-corresponding authors
8. **Braun DA***, et al. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature. 2025 Feb 5. doi: 10.1038/s41586-024-08507-5. Epub ahead of print. PMID: 39910301. *Co-corresponding authors
9. Hugaboom MB, Wirth LV...Atkins MB*, Wu CJ*, **Braun DA***. Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma. Cancer Discov. 2025 Feb 24. doi: 10.1158/2159-8290.CD-24-0991. Epub ahead of print.